{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:10:19Z","timestamp":1791317419911,"version":"4.3.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,1,30]],"date-time":"2009-01-30T00:00:00Z","timestamp":1233273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s11523-008-0100-y","type":"journal-article","created":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T12:29:03Z","timestamp":1233232143000},"page":"3-10","source":"Crossref","is-referenced-by-count":46,"title":["Treatment selection after imatinib resistance in chronic myeloid leukemia"],"prefix":"10.1007","volume":"4","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,1,30]]},"reference":[{"key":"100_CR1","unstructured":"National Comprehensive Cancer Network (2008) Chronic myelogenous leukemia V.I.2008. NCCN Clinical Practice Guidelines in Oncology. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf . Accessed 19 Sept 2008"},{"key":"100_CR2","unstructured":"European LeukemiaNet (2008) Management of chronic myeloid leukemia (CML): recommendations from the European LeukemiaNet (ELN). http:\/\/www.leukemia-net.org\/content\/leukemias\/cml\/standards_sops\/recommendations\/ . Accessed 2 Sept 2008"},{"issue":"1","key":"100_CR3","first-page":"85","volume":"61","author":"JD Griffin","year":"1983","unstructured":"Griffin JD, Todd RF III, Ritz J, Nadler LM, Canellos GP, Rosenthal D et al (1983) Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 61(1):85\u201391","journal-title":"Blood"},{"issue":"3","key":"100_CR4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.1985.tb07326.x","volume":"59","author":"P Bettelheim","year":"1985","unstructured":"Bettelheim P, Lutz D, Majdic O, Paietta E, Haas O, Linkesch W et al (1985) Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia. Br J Haematol 59(3):395\u2013409","journal-title":"Br J Haematol"},{"key":"100_CR5","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330\u20131340","journal-title":"N Engl J Med"},{"issue":"1","key":"100_CR6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.1988.6.1.180","volume":"6","author":"HM Kantarjian","year":"1988","unstructured":"Kantarjian HM, Talpaz M (1988) Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol 6(1):180\u2013182","journal-title":"J Clin Oncol"},{"key":"100_CR7","first-page":"1497","volume":"132","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497","journal-title":"Science"},{"key":"100_CR8","doi-asserted-by":"crossref","first-page":"290\u2212293","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2212293","journal-title":"Nature"},{"key":"100_CR9","first-page":"1079\u22121082","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079\u22121082","journal-title":"Science"},{"key":"100_CR10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","volume":"75","author":"AM Pendergast","year":"1993","unstructured":"Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al (1993) BCRABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175\u2013185","journal-title":"Cell"},{"key":"100_CR11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","volume":"13","author":"L Puil","year":"1994","unstructured":"Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al (1994) Bcr-Abi oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13:764\u2013773","journal-title":"EMBO J"},{"key":"100_CR12","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/j.1460-2075.1995.tb07316.x","volume":"14","author":"R Marais","year":"1995","unstructured":"Marais R, Light Y, Paterson HF, Marshall CJ (1995) Ras remits Raf-I to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 14:3136\u20133145","journal-title":"EMBO J"},{"key":"100_CR13","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","volume":"86","author":"T Skorski","year":"1995","unstructured":"Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G et al (1995) Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726\u2013736","journal-title":"Blood"},{"key":"100_CR14","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","volume":"16","author":"T Skorski","year":"1997","unstructured":"Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al (1997) Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway. EMBO J 16:6151\u20136161","journal-title":"EMBO J"},{"key":"100_CR15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(00)81883-8","volume":"88","author":"TF Franke","year":"1997","unstructured":"Franke TF, Kaplan DR, Cantley LC (1997) PBK: downstream AKTion blocks apoptosis. Cell 88:435\u2013437","journal-title":"Cell"},{"key":"100_CR16","first-page":"247","volume":"13","author":"K Shuai","year":"1996","unstructured":"Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL (1996) Constitutive activation of STAT5 by the Bcr-Abl oncogene in chronic myelogenous leukemia. Oncogene 13:247\u2013254","journal-title":"Oncogene"},{"key":"100_CR17","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Haria Jr","year":"1996","unstructured":"Haria RL Jr, Van Etten RA (1996) P2IO and PI90(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271:31704\u201331710","journal-title":"J Biol Chem"},{"key":"100_CR18","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","volume":"21","author":"A Klejman","year":"2002","unstructured":"Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al (2002) The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21:5766\u20135774","journal-title":"EMBO J"},{"key":"100_CR19","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1073\/pnas.082005599","volume":"99","author":"A Menssen","year":"2002","unstructured":"Menssen A, Hermeking H (2002) Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA 99:6274\u20136279","journal-title":"Proc Natl Acad Sci USA"},{"key":"100_CR20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","volume":"70","author":"CL Sawyers","year":"1992","unstructured":"Sawyers CL, Callahan W, Witte ON (1992) Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70:901\u2013910","journal-title":"Cell"},{"key":"100_CR21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1126\/science.8153630","volume":"264","author":"DE Alar","year":"1994","unstructured":"Alar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL (1994) Differential complementation of Bcr-Abl point mutants with c-Myc. Science 264:424\u2013426","journal-title":"Science"},{"key":"100_CR22","doi-asserted-by":"crossref","first-page":"13137","DOI":"10.1073\/pnas.93.23.13137","volume":"93","author":"T Skorski","year":"1996","unstructured":"Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA et al (1996) Blastic transformation of p53-deficient bone marrow cells by p2lObcr\/abl tyrosine kinase. Proc Natl Acad Sci USA 93:13137\u201313142","journal-title":"Proc Natl Acad Sci USA"},{"key":"100_CR23","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1016\/S0092-8674(00)81079-X","volume":"85","author":"M Serrano","year":"1996","unstructured":"Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:2737","journal-title":"Cell"},{"key":"100_CR24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/10428190009059278","volume":"38","author":"Z Beck","year":"2000","unstructured":"Beck Z, Kiss A, T\u00f3th FD, Szab\u00f3 J, B\u00e1csi A, Balogh E et al (2000) Alterations ofP53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma 38:587\u2013597","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"100_CR25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","volume":"2","author":"C Sherr","year":"2002","unstructured":"Sherr C, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2(2):103\u2013112","journal-title":"Cancer Cell"},{"key":"100_CR26","first-page":"994\u22121004","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u22121004","journal-title":"N Engl J Med"},{"key":"100_CR27","unstructured":"Novartis Pharmaceuticals Corporation (2007) Imatinib prescribing information. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gleevec_tabs.pdf Accessed 16 Oct 2008"},{"key":"100_CR28","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. (2009) Chronic Myelogenous Leukemia http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf . Accessed 15 Oct 2008"},{"key":"100_CR29","doi-asserted-by":"crossref","first-page":"2408\u22122417","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u22122417","journal-title":"N Engl J Med"},{"issue":"18S","key":"100_CR30","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1200\/jco.2007.25.18_suppl.7045","volume":"25","author":"MY Hamdan","year":"2007","unstructured":"Hamdan MY, Sanders L, Oliveria S, Campbell U, Willey V, Hirji I et al (2007) Discontinuation and dose modification of imatinib in clinical practice. J Clin Oncol 25(18S):7045","journal-title":"J Clin Oncol"},{"key":"100_CR31","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530\u20133539","journal-title":"Blood"},{"key":"100_CR32","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928\u20131937","journal-title":"Blood"},{"key":"100_CR33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645\u2013652","journal-title":"N Engl J Med"},{"issue":"2","key":"100_CR34","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","volume":"101","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, Giles F, Garcia-Manero G, Faderl S et al (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2):473\u2013475","journal-title":"Blood"},{"issue":"6","key":"100_CR35","first-page":"2092","volume":"9","author":"JA Zonder","year":"2003","unstructured":"Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA (2003) The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 9(6):2092\u20132097","journal-title":"Clin Cancer Res"},{"key":"100_CR36","doi-asserted-by":"crossref","first-page":"226a","DOI":"10.1182\/blood.V110.11.226.226","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Hochhaus A, Cortes J, Martinelli G, Bhalla KN, Giles FJ et al (2007) Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia patients with imatinib-resistance or intolerance. Blood 110:226a (abstract 735)","journal-title":"Blood"},{"issue":"7","key":"100_CR37","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","volume":"102","author":"D Marin","year":"2003","unstructured":"Marin D, Goldman JM, Olavarria E, Apperley JF (2003) Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 102(7):2702\u20132703","journal-title":"Blood"},{"key":"100_CR38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood-2007-01-070045","volume":"110","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Kantarjian H, Atallah E, Borthakur G, Wierda W, Faderl S et al (2007) Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML). Blood 110:1035","journal-title":"Blood"},{"key":"100_CR39","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Ros\u00e9e P, M\u00fcller MC, Lahaye T et al (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190\u20132196","journal-title":"Leukemia"},{"key":"100_CR40","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690\u2013698","journal-title":"Blood"},{"issue":"2","key":"100_CR41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al (2006) OCT-1\u2013mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108(2):697\u2013704","journal-title":"Blood"},{"issue":"1","key":"100_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","volume":"47","author":"J Goldman","year":"2006","unstructured":"Goldman J, Gordon M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47(1):1\u20137","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"100_CR43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","volume":"102","author":"J Cortes","year":"2003","unstructured":"Cortes J, Giles F, O\u2019Brien S (2003) Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102(1):83\u201386","journal-title":"Blood"},{"key":"100_CR44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"100_CR45","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","volume":"103","author":"HM Kantarjian","year":"2004","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, Garcia-Manero G, Verstovsek S, Giles F et al (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome\u2013positive chronic phase chronic myeloid leukemia. Blood 103:2873\u20132878","journal-title":"Blood"},{"issue":"5","key":"100_CR46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","volume":"36","author":"Y Hu","year":"2004","unstructured":"Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al (2004) Requirement of Src kinases Lyn, Hck and Fgr for Bcr-Abll-induced B-Iymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36(5):453\u2013461","journal-title":"Nat Genet"},{"issue":"11","key":"100_CR47","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nm1127","volume":"10","author":"A Ptasznik","year":"2004","unstructured":"Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABLI(+) leukemia cells. Nat Med 10(11):1187\u20131189","journal-title":"Nat Med"},{"key":"100_CR48","doi-asserted-by":"crossref","first-page":"3207\u22123213","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207\u22123213","journal-title":"Blood"},{"key":"100_CR49","first-page":"4143\u22124150","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ et al (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143\u22124150","journal-title":"Blood"},{"key":"100_CR50","doi-asserted-by":"crossref","first-page":"2303\u22122309","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303\u22122309","journal-title":"Blood"},{"key":"100_CR51","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of frontline imatinib: a randomized phase 2 trial. Blood 109:5143\u20135150","journal-title":"Blood"},{"key":"100_CR52","doi-asserted-by":"crossref","first-page":"2309\u22122315","DOI":"10.1182\/blood-2007-02-073528","volume":"110","author":"O Ottmann","year":"2007","unstructured":"Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA et al (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110:2309\u22122315","journal-title":"Blood"},{"issue":"suppl","key":"100_CR53","doi-asserted-by":"crossref","first-page":"7009a","DOI":"10.1200\/jco.2008.26.15_suppl.7009","volume":"26","author":"MJ Mauro","year":"2008","unstructured":"Mauro MJ, Baccarani M, Cervantes F, Lipton JH, Matloub Y, Sinha R et al (2008) Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 26(suppl):7009a","journal-title":"J Clin Oncol"},{"key":"100_CR54","unstructured":"Shah NP, Rousselot P, Pasquini R, Hamerschlak N, Holowiecki J, Gerard B et al (2006) Dasatinib (D) vs high dose imatinib (lM) in patients with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial. Proc Am Soc Clin Oncol 24:abstract 6507"},{"key":"100_CR55","unstructured":"Martinelli G, Rousselot P, Robak T, Masszi T, Skotnicki A, Hellmann A et al (2007) Comparison of dasatinib to high-dose imatinib in patients who experience imatinib failure: results from a randomized, phase-II trial (CA180017, START-R). Haematologica 92:abstract 0862"},{"key":"100_CR56","unstructured":"Bristol-Myers Squibb Company (2007) Dasatinib prescribing information. http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf . Accessed 16 Oct 2008"},{"key":"100_CR57","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med 354:2531\u20132541","journal-title":"N Engl J Med"},{"key":"100_CR58","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","volume":"12","author":"FR Luo","year":"2006","unstructured":"Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K et al (2006) Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 12:7180\u20137186","journal-title":"Clin Cancer Res"},{"key":"100_CR59","doi-asserted-by":"crossref","unstructured":"Shah NP, Kantarjian HM, Kim DW, R\u00e9a D, Dorlhiac-Llacer PE, Milone JH, et al (2008) Intermittent target inhibition with dasatinib (100\u00a0mg once daily) preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol In press","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"100_CR60","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gatterman N (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540\u20133546","journal-title":"Blood"},{"issue":"15S","key":"100_CR61","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/jco.2008.26.15_suppl.7010","volume":"26","author":"HM Kantarjian","year":"2008","unstructured":"Kantarjian HM, Giles FJ, Hochhaus A, Bhalla KN, Ossenkoppele GJ, Gattermann N et al (2008) Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): updated phase II results. J Clin Oncol 26(15S):7010","journal-title":"J Clin Oncol"},{"key":"100_CR62","doi-asserted-by":"crossref","first-page":"310a","DOI":"10.1182\/blood.V110.11.310.310","volume":"110","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Larson RA, Kantarjian HM, le Coutre P, Baccarani M, Haque A et al (2007) Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis who are resistant or intolerant to imatinib. Blood 110:310a (abstract 1025)","journal-title":"Blood"},{"key":"100_CR63","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P Coutre le","year":"2008","unstructured":"le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N et al (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834\u20131839","journal-title":"Blood"},{"key":"100_CR64","unstructured":"Novartis Pharmaceuticals Corporation. (2007) Nilotinib prescribing information. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tasigna.pdf Accessed 16 Oct 2008"},{"key":"100_CR65","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood.V110.11.473.473","volume":"110","author":"C Gambacorti-Passerini","year":"2007","unstructured":"Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, Martinelli G, Baccarani M, Fischer T et al (2007) Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL. Blood 110:146a (abstract 473)","journal-title":"Blood"},{"key":"100_CR66","first-page":"375","volume":"63","author":"JM Golas","year":"2003","unstructured":"Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63:375\u2013381","journal-title":"Cancer Res"},{"key":"100_CR67","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K et al (2005) NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106:3948\u20133954","journal-title":"Blood"},{"key":"100_CR68","doi-asserted-by":"crossref","first-page":"144a","DOI":"10.1182\/blood.V110.11.144.144","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Cortes J, le Coutre P, Nagler A, Pinilla J, Hochhaus A et al (2007) A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood 110:144a (abstract 469)","journal-title":"Blood"},{"issue":"18S","key":"100_CR69","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1200\/jco.2007.25.18_suppl.7046","volume":"25","author":"AR Craig","year":"2007","unstructured":"Craig AR, Kantarjian HM, Cortes JE, Jones D, Hochhaus A, O\u2019Brien S et al (2007) A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J Clin Oncol 25(18S):7046","journal-title":"J Clin Oncol"},{"key":"100_CR70","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","volume":"98","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes J, Giles FJ, Faderl S, Issa JP et al (2003) Results of decitabine (5\u2019-aza-2\u2019deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98:522\u2013528","journal-title":"Cancer"},{"key":"100_CR71","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","volume":"23","author":"JP Issa","year":"2005","unstructured":"Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S et al (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23:3948\u20133956","journal-title":"J Clin Oncol"},{"issue":"15S","key":"100_CR72","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1200\/jco.2008.26.15_suppl.7021","volume":"26","author":"A Benichou","year":"2008","unstructured":"Benichou A, Khoury HJ, Corm S, Nicolini FE, Craig AR, Humphriss E et al (2008) Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation. J Clin Oncol 26(15S):7021","journal-title":"J Clin Oncol"},{"key":"100_CR73","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","volume":"109","author":"Y Oki","year":"2007","unstructured":"Oki Y, Kantarjian HM, Gharibyan V, Jones D, O\u2019Brien S, Verstovsek S et al (2007) Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109:899\u2013906","journal-title":"Cancer"},{"issue":"4","key":"100_CR74","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","volume":"108","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R et al (2006) Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108(4):1421\u20131423","journal-title":"Blood"},{"key":"100_CR75","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O\u2019Brien S et al (2008) Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112:53\u201355","journal-title":"Blood"},{"key":"100_CR76","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12:7374\u20137379","journal-title":"Clin Cancer Res"},{"issue":"11","key":"100_CR77","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/blood.V110.11.320.320","volume":"110","author":"T Hughes","year":"2007","unstructured":"Hughes T, Saglio G, Martinelli G, Kim DW, Soverini S, Mueller M et al (2007) Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types. Blood 110(11):320","journal-title":"Blood"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-008-0100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-008-0100-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-008-0100-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T04:48:24Z","timestamp":1589518104000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-008-0100-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,30]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1007\/s11523-008-0100-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,30]]}}}